404 related articles for article (PubMed ID: 23749645)
21. Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development.
Jiang CM; Pu CW; Hou YH; Chen Z; Alanazy M; Hebbard L
World J Gastroenterol; 2014 Nov; 20(44):16464-73. PubMed ID: 25469014
[TBL] [Abstract][Full Text] [Related]
22. Lipid metabolism signatures in NASH-associated HCC.--letter.
Kessler SM; Laggai S; Barghash A; Helms V; Kiemer AK
Cancer Res; 2014 May; 74(10):2903-4. PubMed ID: 24778416
[No Abstract] [Full Text] [Related]
23. Toll-like Receptor 4 on Macrophage Promotes the Development of Steatohepatitis-related Hepatocellular Carcinoma in Mice.
Miura K; Ishioka M; Minami S; Horie Y; Ohshima S; Goto T; Ohnishi H
J Biol Chem; 2016 May; 291(22):11504-17. PubMed ID: 27022031
[TBL] [Abstract][Full Text] [Related]
24. Increased hepatic oxidative DNA damage in patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma.
Tanaka S; Miyanishi K; Kobune M; Kawano Y; Hoki T; Kubo T; Hayashi T; Sato T; Sato Y; Takimoto R; Kato J
J Gastroenterol; 2013 Nov; 48(11):1249-58. PubMed ID: 23329365
[TBL] [Abstract][Full Text] [Related]
25. Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma.
Kutlu O; Kaleli HN; Ozer E
Can J Gastroenterol Hepatol; 2018; 2018():8543763. PubMed ID: 30228976
[TBL] [Abstract][Full Text] [Related]
26. SCD1 Expression is dispensable for hepatocarcinogenesis induced by AKT and Ras oncogenes in mice.
Li L; Wang C; Calvisi DF; Evert M; Pilo MG; Jiang L; Yuneva M; Chen X
PLoS One; 2013; 8(9):e75104. PubMed ID: 24069385
[TBL] [Abstract][Full Text] [Related]
27. Myeloid-specific IRE1alpha deletion reduces tumour development in a diabetic, non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model.
Van Campenhout S; Tilleman L; Lefere S; Vandierendonck A; Raevens S; Verhelst X; Geerts A; Van Nieuwerburgh F; Van Vlierberghe H; Devisscher L
Metabolism; 2020 Jun; 107():154220. PubMed ID: 32243868
[TBL] [Abstract][Full Text] [Related]
28. Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice.
Wang B; Majumder S; Nuovo G; Kutay H; Volinia S; Patel T; Schmittgen TD; Croce C; Ghoshal K; Jacob ST
Hepatology; 2009 Oct; 50(4):1152-61. PubMed ID: 19711427
[TBL] [Abstract][Full Text] [Related]
29. Up-regulation of FGF15/19 signaling promotes hepatocellular carcinoma in the background of fatty liver.
Cui G; Martin RC; Jin H; Liu X; Pandit H; Zhao H; Cai L; Zhang P; Li W; Li Y
J Exp Clin Cancer Res; 2018 Jul; 37(1):136. PubMed ID: 29973237
[TBL] [Abstract][Full Text] [Related]
30. Eicosapentaenoic acid ameliorates steatohepatitis and hepatocellular carcinoma in hepatocyte-specific Pten-deficient mice.
Ishii H; Horie Y; Ohshima S; Anezaki Y; Kinoshita N; Dohmen T; Kataoka E; Sato W; Goto T; Sasaki J; Sasaki T; Watanabe S; Suzuki A; Ohnishi H
J Hepatol; 2009 Mar; 50(3):562-71. PubMed ID: 19162361
[TBL] [Abstract][Full Text] [Related]
31. Multifunctional Effects of a Small-Molecule STAT3 Inhibitor on NASH and Hepatocellular Carcinoma in Mice.
Jung KH; Yoo W; Stevenson HL; Deshpande D; Shen H; Gagea M; Yoo SY; Wang J; Eckols TK; Bharadwaj U; Tweardy DJ; Beretta L
Clin Cancer Res; 2017 Sep; 23(18):5537-5546. PubMed ID: 28533225
[No Abstract] [Full Text] [Related]
32. FOXK1 promotes nonalcoholic fatty liver disease by mediating mTORC1-dependent inhibition of hepatic fatty acid oxidation.
Fujinuma S; Nakatsumi H; Shimizu H; Sugiyama S; Harada A; Goya T; Tanaka M; Kohjima M; Takahashi M; Izumi Y; Yagi M; Kang D; Kaneko M; Shigeta M; Bamba T; Ohkawa Y; Nakayama KI
Cell Rep; 2023 May; 42(5):112530. PubMed ID: 37209098
[TBL] [Abstract][Full Text] [Related]
33. TAZ-induced Cybb contributes to liver tumor formation in non-alcoholic steatohepatitis.
Wang X; Zeldin S; Shi H; Zhu C; Saito Y; Corey KE; Osganian SA; Remotti HE; Verna EC; Pajvani UB; Schwabe RF; Tabas I
J Hepatol; 2022 Apr; 76(4):910-920. PubMed ID: 34902531
[TBL] [Abstract][Full Text] [Related]
34. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
Zoller H; Tilg H
Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
[TBL] [Abstract][Full Text] [Related]
35. Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment.
Agosti P; Sabbà C; Mazzocca A
Biochim Biophys Acta Mol Basis Dis; 2018 Feb; 1864(2):607-617. PubMed ID: 29197664
[TBL] [Abstract][Full Text] [Related]
36. The role of hepassocin in the development of non-alcoholic fatty liver disease.
Wu HT; Lu FH; Ou HY; Su YC; Hung HC; Wu JS; Yang YC; Wu CL; Chang CJ
J Hepatol; 2013 Nov; 59(5):1065-72. PubMed ID: 23792031
[TBL] [Abstract][Full Text] [Related]
37. A new preclinical model of western diet-induced progression of non-alcoholic steatohepatitis to hepatocellular carcinoma.
Green CD; Weigel C; Brown RDR; Bedossa P; Dozmorov M; Sanyal AJ; Spiegel S
FASEB J; 2022 Jul; 36(7):e22372. PubMed ID: 35639028
[TBL] [Abstract][Full Text] [Related]
38. Proteome Characteristics of Non-Alcoholic Steatohepatitis Liver Tissue and Associated Hepatocellular Carcinomas.
Kakehashi A; Stefanov VE; Ishii N; Okuno T; Fujii H; Kawai K; Kawada N; Wanibuchi H
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28218651
[TBL] [Abstract][Full Text] [Related]
39. Gp78, an E3 ubiquitin ligase acts as a gatekeeper suppressing nonalcoholic steatohepatitis (NASH) and liver cancer.
Zhang T; Kho DH; Wang Y; Harazono Y; Nakajima K; Xie Y; Raz A
PLoS One; 2015; 10(3):e0118448. PubMed ID: 25789613
[TBL] [Abstract][Full Text] [Related]
40. Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease.
Svegliati-Baroni G; Pierantonelli I; Torquato P; Marinelli R; Ferreri C; Chatgilialoglu C; Bartolini D; Galli F
Free Radic Biol Med; 2019 Nov; 144():293-309. PubMed ID: 31152791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
